Plus: Stipple and Syneron raise megarounds Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 6 April, 2026

John Carroll’s R&D 15 report is back — and this year, he’s bringing some of the industry’s top research chiefs into the conversation to break down what the data means, what’s shifting, and where biopharma R&D is headed. Join us to find out what comes next.

presented by Pre­sent­ing Your Gene Ther­a­py Man­u­fac­tur­ing Plan to In­vestors: What They Ex­pect in 2026 and How to De­liv­er It

news Neurocrine pays $2.9B for Soleno and its Prader-Willi medicine Stipple Bio launches with $100M to find more precise targets on cancer proteins China's Syneron raises $150M for peptides, adding to last year's $100M Trump signs order to put 100% tariffs on drugs, countries without pharma trade deals Diabetes cell therapy startup gets $79M from Canadian government

Head of Regulatory Strategy TCG stealth clinic-ready newco Boston, MA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera

AI has gone from buzzword to pipeline strategy — but are the results a mixed bag? We're talking to the researchers in the thick of it about what's moving the needle, what's stalling out and what comes next. Join us for a free virtual program, then continue the conversation at an in-person-only fireside and happy hour in Boston. Choose your pass.

Endpoints Pharma The tide is starting to turn in pharma's favor for the future of 340B Novo claims that its obesity pill is better than Lilly’s. Only a head-to-head trial can prove it The peptide fad lures health tech Exclusive: OpenLoop has acquired Season Health

in case you missed it 1. Immunovant's FcRn drug fails in a pair of Phase 3 trials in thyroid eye disease 2. Alto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 miss 3. Gilead ends a Phase 2/3 trial of long-acting HIV pills, following earlier clinical hold 4. HHS Takes a First Step Toward Restoring Vaccine Advisory Committee 5. A New Opioid Agonist?

.